BioAlliance Pharma (BIO)

Business description

BioAlliance Pharma is a French drug development company focused on orphan cancer and supportive care treatments. It has two FDA-approved specialty products and three clinical-stage orphan oncology candidates.

Share price chart

Share chart

Stock data

Market cap.US$147.5m
Last closeUS$7.130
High / Low (52 weeks)US$10.5 / US$3.4
Stock market listingEuronext Paris
Forecast net cash (€m)10.9
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(5.3)50.758.5
Relative *(9.1)47.231.0

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Acorda Therapeutics
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarin AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Arena Pharmaceuticals
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Astex Pharmaceuticals
Athersys AVEO Pharmaceuticals
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
BTG Can-Fite BioPharma
Cardio3 BioSciences Celldex Therapeutics
Cellectis Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Clinuvel
Consort Medical Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Futura Medical Galapagos
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunodiagnostic Systems Holdings
ImmuPharma Imperial Innovations
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MolMed
Mologen AG MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo OvaScience
Oxford BioMedica Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prima BioMed
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Regeneus Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes Stem Cell Therapeutics
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trimel Pharmaceuticals UCB
United Drug Vectura
Verastem Verisante Inc
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Zealand Pharma Zeltia
Ziopharm Oncology
Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2011A 3.2 (15.3) (14.6) (83.00) N/A N/A
2012A 4.0 (12.1) (11.5) (65.00) N/A N/A
2013E 3.8 (13.1) (12.8) (66.42) N/A N/A
2014E 6.3 (10.7) (10.4) (50.48) N/A N/A

Last updated on 27/03/2014

Investment summary

2014 will be a critical year for BioAlliance, with key proof-of-concept data from the large ongoing Phase II trial for oral mucositis product Validive by end 2014. Furthermore, additional planned safety assessments will help to further de-risk Livatig, currently in Phase III development for liver cancer with headline data expected in H116. Sitavig (cold sores) was recently partnered in the US in exchange for $5m in upfront and milestone payments in addition to double-digit royalties; US launch is expected in Q314.

Last updated on 31/03/2014

Industry outlook

BioAlliance develops drugs for orphan oncology indications and to treat infection. Most of its products are widely used medicines in new formulations for novel indications, which either address significant unmet medical needs or have a clear point of differentiation over current treatments. The former are the more valuable, but the latter still have considerable commercial potential.

Last updated on 31/03/2014

Key management

Judith Greciet, CEO
Nicolas Fellmann, CFO
Pierre Attali, COO

Company address

49 Boulevard du Général Matrial Valin
Paris
75015
France
+33 (0)1 45 58 71 00
View website